1 |
Ferrero JM, Foa C, Thezenas S, et al (2004). A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology, 66, 281-7.
DOI
|
2 |
Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8.
DOI
|
3 |
de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-54.
DOI
|
4 |
Garcia JA, Elson P, Tyler A, et al (2014). Sargramostim (GMCSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol, 32, 11-7.
|
5 |
Hurria A, Fleming MT, Baker SD, et al (2006). Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res, 12, 6100-5.
DOI
|
6 |
Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-22.
DOI
|
7 |
Keizman D, Zahurak M, Sinibaldi V, et al (2010). Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res, 16, 5269-76.
DOI
|
8 |
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol, 14, 117-24.
DOI
|
9 |
Luo HC, Cheng HH, Lin GS, et al (2013). Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients. Asian Pac J Cancer Prev, 14, 4711-5.
DOI
|
10 |
Nabhan C, Petrylak DP (2012). The role of IMiDs alone or in combination in prostate cancer. Clin Genitourin Cancer, 10, 141-6.
DOI
|
11 |
Nabhan C, Patel A, Villines D, et al (2014). Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clin Genitourin Cancer, 12, 27-32.
DOI
|
12 |
Nelson WG, De Marzo AM, Isaacs WB (2003). Prostate cancer. N Engl J Med, 349, 366-81.
DOI
|
13 |
Parker C, Nilsson S, Heinrich D, et al (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 369, 213-23.
DOI
|
14 |
Pazdur R (2013). FDA Approval for Docetaxel. Available:http://www.cancer.gov/cancertopics/druginfo/fda-docetaxel.
|
15 |
Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20.
DOI
|
16 |
Scher HI, Fizazi K, Saad F, et al (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 1187-97.
DOI
|
17 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
18 |
de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005.
DOI
|
19 |
Baker SD, Zhao M, Lee CK, et al (2004). Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res, 10, 1976-83.
DOI
|
20 |
Berry W, Dakhil S, Gregurich MA (2001). Asmar L Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol, 28, 8-15.
DOI
|
21 |
de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376, 1147-54.
DOI
|
22 |
Du LB, Li HZ, Wang XH, et al (2014). Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev, 15, 5839-43.
DOI
|